Health1 min read

Could one daily pill narrow the diabetes treatment gap in the Global South?

By · Published by Everything Blog

In short

The shift to oral GLP-1 tablets eliminates the fragile cold-chain refrigeration networks that typically complicate the delivery of injectable drugs and insulin. This logistical improvement is crucial for nations facing severe crises, such as Pakistan, where adult diabetes prevalence has reached 31.4 percent. Furthermore, generic domestic manufacturing offers massive affordability gains, providing a 30-day supply of oral semaglutide for approximately $18, compared to hundreds of dollars for imported brand-name alternatives.

Key points

  • Transitioning to oral medications removes the dependency on cold-chain refrigeration, vas…: Transitioning to oral medications removes the dependency on cold-chain refrigeration, vastly simplifying distribution across rural and lower-income regions.
  • GLP-1 therapies improve blood sugar control while addressing related health conditions su…: GLP-1 therapies improve blood sugar control while addressing related health conditions such as kidney outcomes, liver disease, and sleep apnea.
  • Medical experts emphasize that obesity is a metabolic disorder requiring medical interven…: Medical experts emphasize that obesity is a metabolic disorder requiring medical intervention rather than a personal behavioral failure.

Sources checked by our analysis pipeline: 1

Globally, one in nine people lives with diabetes, as blockbuster injectable drugs begin making way for tablets instead.

Medication that has been a lifeline for patients with uncontrollable diabetes is now slowly shifting from injections to pills, a move that could fundamentally alter treatment for the disease – and who can access it.

This shift could also affect the treatment of obesity, a long misunderstood condition once associated with overeating and laziness, rather than the metabolic disorder it is now recognised as.

Recommended Stories

list of 4 items- list 1 of 4Can GLP-1 drugs like Ozempic cause vision loss? What we know about the risk

- list 2 of 4Sweet scoop: Ice-cream study points to potential sugar substitute

- list 3 of 4Food or medicine? The impossible choices facing Sudan’s chronically ill

- list 4 of 4With every rainfall, Gaza risks losing access to power and healthcare

GLP-1 (glucagon-like peptide-1) receptor agonists therapy isn’t new. The first FDA-approved drug, Exenatide, hit the market in 2005 and was followed by Liraglutide in 2009, which was seen as a revolutionary alternative to…

Health